I don't disagree that there will be a chance to stop the trial with interim results, in fact I point out the second interim results may well result in an early stop.
To be clear, the first interim read- out for the Phase 3 CHF trial will only test for surrogates i.e. indicators of how the treatment is performing and not endpoint data.
The second interim read-out will be triggered once approx. 50% of events have been recorded and at this stage an early stop to the trial and fast track to approval could be achieved.
All I wanted to point out is that they are not likely to change the way the trial will be run at this late stage, as far as we can tell a placebo will be used for the phase 3 CHF trial.
$5.8 Billion, page-40
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |